KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to -$10.5 million.

  • Aurinia Pharmaceuticals' Cash from Financing Activities fell 285.38% to -$10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.3 million, marking a year-over-year decrease of 302.45%. This contributed to the annual value of -$49.1 million for FY2024, which is 856.96% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$10.5 million for Q3 2025, which was up 76.37% from -$44.4 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash from Financing Activities peaked at $205.7 million during Q4 2021, and registered a low of -$49.3 million during Q1 2025.
  • Its 3-year average for Cash from Financing Activities is -$14.4 million, with a median of -$8.3 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 16,463.77% in 2021, then slumped by 1,018.30% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $205.7 million in 2021, then crashed by 99.67% to $688,000 in 2022, then crashed by 910.61% to -$5.6 million in 2023, then slumped by 313.23% to -$23.0 million in 2024, then tumbled by 285.38% to -$10.5 million in 2025.
  • Its Cash from Financing Activities was -$10.5 million in Q3 2025, compared to -$44.4 million in Q2 2025 and -$49.3 million in Q1 2025.